Fintel reports that on April 21, 2025, Wolfe Research upgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from ...

Intellia Therapeutics has said it will reduce its ... its resources behind two priority drug candidates. The specialist in CRISPR-based gene editing – co-founded by Nobel Prize winner Jennifer ...

CRISPR and CRISPR-Associated Gene Market Set to Surge to $20 Billion by 2035, Fueled by Technological Breakthroughs and Biotech Investments The global CRISPR and CRISPR-Associated Gene Market Size is ...

Intellia has reported results from a phase ... Earlier this year, Vertex Pharma and CRISPR Therapeutics' Casgevy (exagamglogene autotemcel) for sickle cell disease and beta thalassaemia became ...

As of early 2025, CRISPR Therapeutics, Intellia Therapeutics, and PagerDuty were examples. To some extent, the portfolio’s liquidity risk has receded in recent years—but not by design.

Story Feb. 28 - CRISPR Therapeutics ... It is not making the figures public. Story Jan. 10 - Intellia Therapeutics: Exactly one year after slashing 15% of its workforce and pausing some research ...

As previously reported, Wolfe Research analyst Andy Chen upgraded Intellia Therapeutics (NTLA) to Outperform from Peer Perform with a $21 price ...

Shares of Intellia Therapeutics (NASDAQ:NTLA) were up over 10% on Monday, after Wolfe Research upgraded the company to Outperform from Peer Perform.

Wolfe Research upgraded Intellia Therapeutics (NTLA) to Outperform from Peer Perform with a $21 price target Stay Ahead of the Market: ...

In the latest market close, CRISPR Therapeutics AG (CRSP) reached $37.77, with a -0.03% movement compared to the previous day. This change lagged the S&P 500's 0.13% gain on the day. On the other ...

Genome editing has advanced at a rapid pace with promising results for treating genetic conditions-but there is always room for improvement.